Christian Weyer
President chez Escient Pharmaceuticals, Inc.
Profil
Christian Weyer is the President & Chief Medical Officer at Escient Pharmaceuticals, Inc. He was previously the President, Chief Executive Officer & Director at Fate Therapeutics, Inc. and Senior Vice President-Research & Development at Amylin Pharmaceuticals, Inc. He also served as the Executive Vice President-Research & Development at Intercept Pharmaceuticals, Inc. In addition, he was the President & Chief Development Officer at Profil Institute for Clinical Research, Inc. and ProSciento, Inc. Dr. Weyer holds a graduate degree from the University of California San Diego and a doctorate from Heinrich-Heine-Universität Düsseldorf.
Postes actifs de Christian Weyer
| Sociétés | Poste | Début |
|---|---|---|
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | President | 18/05/2021 |
Anciens postes connus de Christian Weyer
| Sociétés | Poste | Fin |
|---|---|---|
Profil Institute for Clinical Research, Inc.
 Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | President | 01/11/2017 |
ProSciento, Inc.
 ProSciento, Inc. Miscellaneous Commercial ServicesCommercial Services ProSciento, Inc. is a full-service clinical research organization that works with biopharma companies worldwide to support their outsourced clinical research needs. The company is based in Chula Vista, CA, and has subsidiaries in the United States. The company specializes in providing comprehensive and customized services for multinational, early development clinical trial programs for metabolic continuum diseases, including diabetes, obesity, and steatotic liver disease. ProSciento has conducted over 300 clinical projects and supported the development of many approved metabolic drugs and devices on the market. ProSciento was founded in 2003, and Marcus Hompesch has been the CEO of the company since its inception. | President | 01/11/2017 |
| FATE THERAPEUTICS, INC. | Directeur Général | 01/11/2015 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
| INTERCEPT PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Christian Weyer
| University of California San Diego | Graduate Degree |
| Heinrich-Heine-Universität Düsseldorf | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
EKF-diagnostic GmbH
 EKF-diagnostic GmbH Medical SpecialtiesHealth Technology EKF-diagnostic GmbH engages in the development, manufacture, and distribution of medical equipment. It produces point of care analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and glycated hemoglobin. Its products include Quo-Test, Quo-Lab, Biosen, CardioChek Plus, Lactate Scout+, Hemo Control, Crematocrit Plus, Hemo Vet, and DiaSpectTM. The company was founded by Berthold Walter in 1990 and is headquartered in Barleben, Germany. | Health Technology |
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | Commercial Services |
ProSciento, Inc.
ProSciento, Inc. Miscellaneous Commercial ServicesCommercial Services ProSciento, Inc. is a full-service clinical research organization that works with biopharma companies worldwide to support their outsourced clinical research needs. The company is based in Chula Vista, CA, and has subsidiaries in the United States. The company specializes in providing comprehensive and customized services for multinational, early development clinical trial programs for metabolic continuum diseases, including diabetes, obesity, and steatotic liver disease. ProSciento has conducted over 300 clinical projects and supported the development of many approved metabolic drugs and devices on the market. ProSciento was founded in 2003, and Marcus Hompesch has been the CEO of the company since its inception. | Commercial Services |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
